Chronic leukemia is divided into chronic granulocytic leukemia and chronic lymphocytic leukemia, referred to as slow granulocyte and slow gonorrhea. Most patients with slow granulocyte can achieve long-term survival with targeted therapy, while the survival of slow gonorrhea depends on the risk stratification of the disease, with low-risk patients also surviving up to 10 years or more.
Chronic leukemia is a malignant clonal disease of hematopoietic stem cells with a characteristic ph chromosome and bcr-abl fusion gene, which is the main target of targeted therapy for this disease. It is mainly a disease with increased infantile cells in peripheral blood or bone marrow, with impaired immune regulation and abnormal immunoglobulins. Chronic gonorrhea is currently treated with targeted drugs tyrosine kinase inhibitors, and most patients can achieve long-term disease-free survival. Patients with early stage chronic gonorrhea have an average survival of up to about 10 years if their disease is stable, but the average survival is significantly shorter if there is a gene mutation of poor prognosis type.
Patients with chronic leukemia should strengthen self-protection, prevent infection and bleeding, and avoid going to public places to contact infectious patients. They should also pay attention to the adherence to medication as prescribed by their doctors and regularly review their peripheral blood picture.